Friday, July 5, 2019 Daily Archives

CDMO Celonic jumping into cell & gene therapies with €50m plant

by

Following a €50 million ($56 million) investment in its biomanufacturing capabilities, Celonic is spending a similar amount to propel itself into the commercial cell and gene therapy space. Contract development and manufacturing organization (CDMO) Celonic announced last year the construction of a GMP facility at its site in Heidelberg, Germany, increasing clean room area by approximately 2,000 square meters to support clients’ Phase III and commercial biologics programs. CEO Konstantin Matentzoglu told Bioprocess Insider on stage at BIO that the…

July 5, 2019

Ohr pushes for oligonucleotide merger with NeuBase

by

Ohr Pharmaceutical has urged its shareholders to vote for a merger with Neubase Therapeutics at a special meeting this week, creating an entity focused on RNA gene silencing. The reverse merger, first announced in January, would create a public company focused on advancing NeuBase’s peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL) technology platform for the development of therapies to address severe diseases caused by genetic mutations, including Huntington’s disease and myotonic dystrophy. However, the deal is at risk of not going…

July 5, 2019

Teva partnership looks to up its biologics productivity

by

Teva has teamed with Just Biotherapeutics to develop a high productivity biomanufacturing process as it focuses its efforts towards biopharmaceuticals. The partnership aims to develop methods to lower the cost of biomanufacturing. Just Biotherapeutics – recently acquired by Germany’s Evotec – will design and development a high yielding manufacturing process for one of Teva Pharmaceutical Industries’ complex products. Further details of the process, molecule or the finances of the deal were not answered by either company when contacted by this…

July 5, 2019